April 25 (Reuters) - AbbVie ( ABBV ) said on Thursday
its drug, Rinvoq, for treating a type of inflammatory skin
condition showed superior efficacy to Regeneron Pharmaceuticals ( REGN )
and Sanofi's Dupixent in a late-stage
head-to-head study.